- Home
- OVID vs MAIA Comparison
OVID vs MAIA Comparison
Compare OVID & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- MAIA
- Stock Information
- Founded
- OVID 2014
- MAIA 2018
- Country
- OVID United States
- MAIA United States
- Employees
- OVID N/A
- MAIA N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- MAIA Health Care
- Exchange
- OVID Nasdaq
- MAIA Nasdaq
- Market Cap
- OVID 47.1M
- MAIA 52.8M
- IPO Year
- OVID 2017
- MAIA 2022
- Fundamental
- Price
- OVID $0.62
- MAIA $1.85
- Analyst Decision
- OVID Strong Buy
- MAIA
- Analyst Count
- OVID 6
- MAIA 0
- Target Price
- OVID $4.03
- MAIA N/A
- AVG Volume (30 Days)
- OVID 467.5K
- MAIA 355.9K
- Earning Date
- OVID 03-07-2025
- MAIA 03-20-2025
- Dividend Yield
- OVID N/A
- MAIA N/A
- EPS Growth
- OVID N/A
- MAIA N/A
- EPS
- OVID N/A
- MAIA N/A
- Revenue
- OVID $631,695.00
- MAIA N/A
- Revenue This Year
- OVID $71.38
- MAIA N/A
- Revenue Next Year
- OVID N/A
- MAIA N/A
- P/E Ratio
- OVID N/A
- MAIA N/A
- Revenue Growth
- OVID 113.21
- MAIA N/A
- 52 Week Low
- OVID $0.56
- MAIA $1.24
- 52 Week High
- OVID $3.79
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- OVID 38.62
- MAIA 44.20
- Support Level
- OVID $0.56
- MAIA $1.83
- Resistance Level
- OVID $0.67
- MAIA $1.94
- Average True Range (ATR)
- OVID 0.06
- MAIA 0.15
- MACD
- OVID 0.00
- MAIA 0.01
- Stochastic Oscillator
- OVID 35.94
- MAIA 15.09
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.